Effect of Isoprenaline or Stress on Adrenaline-Induced Arrhythmias in Albino Rats

  • P. K. Das
  • S. Bhowmick
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 68)


Rona et al. (1) described for the first time that isoprenaline (ISP) produces infarct-like myocardial lesions in experimental animals. Since then the ISP model has been widely used to understand the pathophysiology of myocardial ischemia. During the subsequent years it has been reported that rat-myocardium develops relative insensitivity to the necrosis-inducing effects of ISP after a prior exposure to myocardial insults (2,3,4,5). Selye et al. (2) showed that ligation of the left coronary artery provided resistance against ISP-induced myocardial necrosis in rat. This resistance was reported to be maximal after 48 hr after coronary ligation and then gradually declined, the myocardium regaining sensitivity 3 wk after coronary ligation (3). Balazs et al. (4) found that myocardial resistance to ISP challenge occurred in rats pretreated with ISP for 2 consecutive days, and that the sensitivity had returned 11 wk after the initial treatment. The development of resistance was found to be dependent on the initial production of myocardial lesions, and not on the size of the necrosis (5). In a subsequent study, it was reported that it took at least 5 days for the myocardial resistance to develop after a single dose of ISP, and the normal myocardial sensitivity after multiple doses of ISP did not return even after 19–20 wk of the initial insult (6). In another study it has been reported that rats which were pretreated with ISP have more hypoxic tolerance 14 days after pretreatment with ISP than after 48 hr (7).


Cholinergic System Atropine Sulphate Coronary Ligation Arrhythmogenic Effect Atropine Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rona, G., Chappel, C.I., Balazs, T. and Gaudry, R. Arch. Pathol. 67: 443–445, 1959.Google Scholar
  2. 2.
    Selye, H., Veilleux, R. and Grasso, S. Proc. Soc. Exp. Biol. Med. 104: 343–345, 1960.PubMedGoogle Scholar
  3. 3.
    Dusek, J., Rona, G. and Kahn, D.S. J. Pathol. 105: 279–282, 1971.PubMedCrossRefGoogle Scholar
  4. 4.
    Balazs, T., Ohtake, S. and Noble, J.F. Toxicol. Appl. Pharmacol. 21: 200–213, 1972.PubMedCrossRefGoogle Scholar
  5. 5.
    Balazs, T. Toxicol. 2: 247–255, 1974.CrossRefGoogle Scholar
  6. 6.
    Joseph, X., Bloom, S., Pledger, G. and Balazs, T. Toxicol. Appl. Pharmacol. 69: 199–205, 1983.PubMedCrossRefGoogle Scholar
  7. 7.
    Bhatia, B., Datta, K. and Nijhawan, R. In: Advances in Myocardiology II (Eds. M. Tajuddin, B. Bhatia, H.H. Siddiqui and G. Rona), University Park Press, Baltimore. 1980, pp. 153–163.Google Scholar
  8. 8.
    Leon, A.S. Med.Clinics North Am. 69: 3–20, 1985.Google Scholar
  9. 9.
    Das, P.K. and Bhattacharya, S.K. Brit. J. Pharmacol. 44: 397–403, 1972.Google Scholar
  10. 10.
    Das, P.K. and Sinha, P.S. Brit. J. Pharmacol. 44: 391–397, 1972.Google Scholar
  11. 11.
    Das, P.K. and Bhattacharya, S.K. In: Advances in Myocardiology VI (Eds. M. Tajuddin, B. Bhatia, H.H. Siddiqui and G. Rona), University Park Press, Baltimore, 1980,p. 85–115.Google Scholar
  12. 12.
    Das, P.K., Bhattacharya, T.K. and Gambhir, S.S. In.: Advances in Myocardiology VI(Eds. N.S. Dhalla and D.J. Hearse), Plenum Publishing Corp., 1985,pp. 349–365.Google Scholar
  13. 13.
    Anand, B.K. Am. J. Physiol. 168: 218–225. 1952.PubMedGoogle Scholar
  14. 14.
    Richter, D. and Crossland, J. Am. J. Physiol. 159: 247–251, 1949.PubMedGoogle Scholar
  15. 15.
    Chang, H.Y., Kelin, R.M. and Kunos, G. J. Pharmacol. Exp. Ther. 221: 784–789, 1982.Google Scholar
  16. 16.
    Kenakin, T.P. and Ferris, R.M. J. Cardiovasc. Pharmacol. 5: 90–97, 1983.PubMedCrossRefGoogle Scholar
  17. 17.
    Stadel, J.F., Strulovici, B., Nombi, P., Lavin, T.N., Briggs, M., Caron, M.G. and Lefkowitz, R.J. J. Biol. Chem. 258: 3032–3038. 1983.PubMedGoogle Scholar
  18. 18.
    Davies, A.O. and Lefkowitz, R.J. J. Clin. Invest. 71: 565–571, 1983.PubMedCrossRefGoogle Scholar
  19. 19.
    Hayes, J.S., Pollock, G.D. and Fuller, R.W. J. Pharmacol. Exp. Ther. 231: 633–639, 1984.PubMedGoogle Scholar
  20. 20.
    American Heart Association Subcommittee on Exercise/Cardiac Rehabilitation. Circulation. 64: 1302–1304, 1981.Google Scholar
  21. 21.
    Hammond, H.K. and Froelicher, V.F. Med. Clinics North Am. 69: 21–39, 1985.Google Scholar
  22. 22.
    Williams, R.S. Cardiovasc. Res. 14: 177–182, 1980.PubMedCrossRefGoogle Scholar
  23. 23.
    Ekstrom, J. Q. J. Exp. Physiol. 59: 73–80, 1974.Google Scholar
  24. 24.
    Raab, W., Stark, E., Macmilan, W.H. and Gigee, W.R. Am. J. Cardiol. 8: 203–211, 1961.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • P. K. Das
    • 1
  • S. Bhowmick
    • 1
  1. 1.Department of Pharmacology, Faculty of MedicineAl-Fateh UniversityTripoliLibya

Personalised recommendations